Cargando…

Pharmacokinetics and tissue distribution of four major bioactive components of Cynanchum auriculatum extract: a UPLC–MS/MS study in normal and functional dyspepsia rats

Introduction: Cynanchum auriculatum (CA) is usually used to treat digestive disorders, such as anorexia, enteritis, dysentery, and indigestion. Functional dyspepsia (FD) is characterized by a group of symptoms associated with the gastroduodenal region. Recent pharmacological studies have demonstrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jia, Meng, Xin, Huang, Di, Gong, Zipeng, Liu, Chunhua, Liu, Ting, Pan, Jie, Lu, Yuan, Zheng, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616469/
https://www.ncbi.nlm.nih.gov/pubmed/37915410
http://dx.doi.org/10.3389/fphar.2023.1279971
_version_ 1785129403815034880
author Sun, Jia
Meng, Xin
Huang, Di
Gong, Zipeng
Liu, Chunhua
Liu, Ting
Pan, Jie
Lu, Yuan
Zheng, Lin
author_facet Sun, Jia
Meng, Xin
Huang, Di
Gong, Zipeng
Liu, Chunhua
Liu, Ting
Pan, Jie
Lu, Yuan
Zheng, Lin
author_sort Sun, Jia
collection PubMed
description Introduction: Cynanchum auriculatum (CA) is usually used to treat digestive disorders, such as anorexia, enteritis, dysentery, and indigestion. Functional dyspepsia (FD) is characterized by a group of symptoms associated with the gastroduodenal region. Recent pharmacological studies have demonstrated the efficacy of CA for treating FD. However, the pharmacokinetics (PK) and tissue distribution of CA in physiological and FD states is still unclear. The present study aimed to clarify the differences in PK parameters and tissue distribution of the four major active components of CA (baishouwu benzophenone, deacylmet-aplexigenin, qingyangshengenin, and syringic acid) under both physiological and FD states. Methods: For this, normal and FD rats were orally administered 10 mg/kg CA extract. Then, plasma and tissue (heart, liver, spleen, lung, kidney, brain, stomach, and small intestine) samples were obtained. The four active components of CA in rat plasma and tissues were quantified by developing and validating a fast and reliable ultra–high–performance liquid chromatography–mass spectrometry method. Results: The area under the plasma concentration–time curve from time zero to time t (AUC(0-t)) of baishouwu benzophenone was significantly lower in the FD group than in the normal group (p < 0.01). The FD group had significantly lower (p < 0.001) apparent volume of distribution and plasma clearance of qing-yangshengenin and significantly higher (p < 0.05) AUC(0-t) of deacylmetaplexigenin and qingyangshengenin. The four active components were rapidly distributed into various tissues, and the main target organs of CA activity were the stomach and small intestine. In addition, baishouwu benzophenone, deacylmetaplexigenin, and qingyangshengenin could cross the blood-brain barrier, indicating that the brain may be another target organ in the treatment of FD. Discussion: These results indicate that the pathological state of FD alters the PK behavior and tissue distribution characteristics of baishouwu benzophenone, deacylmetaplexigenin, qingyangshengenin, and syringic acid in the CA extract, providing an experimental basis for the role of CA in FD treatment.
format Online
Article
Text
id pubmed-10616469
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106164692023-11-01 Pharmacokinetics and tissue distribution of four major bioactive components of Cynanchum auriculatum extract: a UPLC–MS/MS study in normal and functional dyspepsia rats Sun, Jia Meng, Xin Huang, Di Gong, Zipeng Liu, Chunhua Liu, Ting Pan, Jie Lu, Yuan Zheng, Lin Front Pharmacol Pharmacology Introduction: Cynanchum auriculatum (CA) is usually used to treat digestive disorders, such as anorexia, enteritis, dysentery, and indigestion. Functional dyspepsia (FD) is characterized by a group of symptoms associated with the gastroduodenal region. Recent pharmacological studies have demonstrated the efficacy of CA for treating FD. However, the pharmacokinetics (PK) and tissue distribution of CA in physiological and FD states is still unclear. The present study aimed to clarify the differences in PK parameters and tissue distribution of the four major active components of CA (baishouwu benzophenone, deacylmet-aplexigenin, qingyangshengenin, and syringic acid) under both physiological and FD states. Methods: For this, normal and FD rats were orally administered 10 mg/kg CA extract. Then, plasma and tissue (heart, liver, spleen, lung, kidney, brain, stomach, and small intestine) samples were obtained. The four active components of CA in rat plasma and tissues were quantified by developing and validating a fast and reliable ultra–high–performance liquid chromatography–mass spectrometry method. Results: The area under the plasma concentration–time curve from time zero to time t (AUC(0-t)) of baishouwu benzophenone was significantly lower in the FD group than in the normal group (p < 0.01). The FD group had significantly lower (p < 0.001) apparent volume of distribution and plasma clearance of qing-yangshengenin and significantly higher (p < 0.05) AUC(0-t) of deacylmetaplexigenin and qingyangshengenin. The four active components were rapidly distributed into various tissues, and the main target organs of CA activity were the stomach and small intestine. In addition, baishouwu benzophenone, deacylmetaplexigenin, and qingyangshengenin could cross the blood-brain barrier, indicating that the brain may be another target organ in the treatment of FD. Discussion: These results indicate that the pathological state of FD alters the PK behavior and tissue distribution characteristics of baishouwu benzophenone, deacylmetaplexigenin, qingyangshengenin, and syringic acid in the CA extract, providing an experimental basis for the role of CA in FD treatment. Frontiers Media S.A. 2023-10-17 /pmc/articles/PMC10616469/ /pubmed/37915410 http://dx.doi.org/10.3389/fphar.2023.1279971 Text en Copyright © 2023 Sun, Meng, Huang, Gong, Liu, Liu, Pan, Lu and Zheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Sun, Jia
Meng, Xin
Huang, Di
Gong, Zipeng
Liu, Chunhua
Liu, Ting
Pan, Jie
Lu, Yuan
Zheng, Lin
Pharmacokinetics and tissue distribution of four major bioactive components of Cynanchum auriculatum extract: a UPLC–MS/MS study in normal and functional dyspepsia rats
title Pharmacokinetics and tissue distribution of four major bioactive components of Cynanchum auriculatum extract: a UPLC–MS/MS study in normal and functional dyspepsia rats
title_full Pharmacokinetics and tissue distribution of four major bioactive components of Cynanchum auriculatum extract: a UPLC–MS/MS study in normal and functional dyspepsia rats
title_fullStr Pharmacokinetics and tissue distribution of four major bioactive components of Cynanchum auriculatum extract: a UPLC–MS/MS study in normal and functional dyspepsia rats
title_full_unstemmed Pharmacokinetics and tissue distribution of four major bioactive components of Cynanchum auriculatum extract: a UPLC–MS/MS study in normal and functional dyspepsia rats
title_short Pharmacokinetics and tissue distribution of four major bioactive components of Cynanchum auriculatum extract: a UPLC–MS/MS study in normal and functional dyspepsia rats
title_sort pharmacokinetics and tissue distribution of four major bioactive components of cynanchum auriculatum extract: a uplc–ms/ms study in normal and functional dyspepsia rats
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616469/
https://www.ncbi.nlm.nih.gov/pubmed/37915410
http://dx.doi.org/10.3389/fphar.2023.1279971
work_keys_str_mv AT sunjia pharmacokineticsandtissuedistributionoffourmajorbioactivecomponentsofcynanchumauriculatumextractauplcmsmsstudyinnormalandfunctionaldyspepsiarats
AT mengxin pharmacokineticsandtissuedistributionoffourmajorbioactivecomponentsofcynanchumauriculatumextractauplcmsmsstudyinnormalandfunctionaldyspepsiarats
AT huangdi pharmacokineticsandtissuedistributionoffourmajorbioactivecomponentsofcynanchumauriculatumextractauplcmsmsstudyinnormalandfunctionaldyspepsiarats
AT gongzipeng pharmacokineticsandtissuedistributionoffourmajorbioactivecomponentsofcynanchumauriculatumextractauplcmsmsstudyinnormalandfunctionaldyspepsiarats
AT liuchunhua pharmacokineticsandtissuedistributionoffourmajorbioactivecomponentsofcynanchumauriculatumextractauplcmsmsstudyinnormalandfunctionaldyspepsiarats
AT liuting pharmacokineticsandtissuedistributionoffourmajorbioactivecomponentsofcynanchumauriculatumextractauplcmsmsstudyinnormalandfunctionaldyspepsiarats
AT panjie pharmacokineticsandtissuedistributionoffourmajorbioactivecomponentsofcynanchumauriculatumextractauplcmsmsstudyinnormalandfunctionaldyspepsiarats
AT luyuan pharmacokineticsandtissuedistributionoffourmajorbioactivecomponentsofcynanchumauriculatumextractauplcmsmsstudyinnormalandfunctionaldyspepsiarats
AT zhenglin pharmacokineticsandtissuedistributionoffourmajorbioactivecomponentsofcynanchumauriculatumextractauplcmsmsstudyinnormalandfunctionaldyspepsiarats